The Absorption Study

PKU (Phenylketonuria) is a rare genetic disease that causes a build-up of phenylalanine - a natural amino acid that is found in the human body. Approximately 1 in 10,000 babies born in Australia are affected.

Left untreated this genetic mutation can lead to intellectual disability in children, behavioural problems, attention deficit disorders, epilepsy, depression, and anxiety.

Patients with PKU currently have very limited treatment options. There are only two medications approved, one of which is not effective for most patients. The other medication requires up to 3 daily injections and has an increased risk of serious allergic reactions. Due to the limited treatment options, it is important that more efficient treatments are developed!

The Study Details:
The Absorption Study medication is administered as an oral table. The study aims to understand how our bodies process the medication, especially when combined with other medications.

Ultimately, this research will help doctors prescribe the Absorption Study medication alongside other treatments, ensuring it’s super effective in managing PKU symptoms. So, it’s not just science; it’s a step toward better health!

This clinical trial has been approved by an independent ethics committee, and you will be reimbursed for your time.

Call us on 1800 243 733 to discuss your eligibility today!